Last quarter (Q2 2023), RUA Life Sciences's total revenue was £―, a decrease of ― from the same quarter last year. In Q2, RUA Life Sciences's net income was £―. See RUA Life Sciences’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Mar 23	Mar 22	Mar 21	Mar 20	Mar 19
Total Revenue	-	£ 2.18M	£ 1.63M	£ 1.53M	£ 489.00K	£ 463.00K
Cost of Revenue	-	£ 388.00K	£ 267.00K	£ 276.00K	£ 0.00	-
Gross Profit	-	£ 1.79M	£ 1.36M	£ 1.25M	£ 489.00K	-
Operating Expense	-	£ 4.17M	£ 3.78M	£ 2.81M	£ 1.39M	£ 1.09M
Operating Income	-	£ -2.38M	£ -2.42M	£ -1.56M	£ -904.00K	£ -632.00K
Net Non Operating Interest Income Expense	-	£ -16.00K	£ -8.00K	£ -43.00K	£ 44.00K	£ 29.00K
Other Income Expense	-	£ -72.00K	£ -66.00K	-	-	-
Pretax Income	-	£ -2.32M	£ -2.36M	£ -1.59M	£ -897.00K	£ -609.00K
Tax Provision	-	£ -319.00K	£ -293.00K	£ -143.00K	£ -81.00K	£ 0.00
Earnings From Equity Interest Net Of Tax	-	-	-	-	-	-
Net Income Common Stockholders	-	£ -2.00M	£ -2.07M	£ -1.45M	£ -816.00K	£ -609.00K
Basic EPS	-	£ -0.09	£ -0.09	£ -0.08	£ -0.06	£ -0.05
Diluted EPS	-	£ -0.09	£ -0.09	£ -0.08	£ -0.06	£ -0.05
Basic Average Shares	-	£ 22.18M	£ 22.18M	£ 17.70M	£ 14.77M	£ 12.98M
Diluted Average Shares	-	£ 22.18M	£ 22.18M	£ 17.70M	£ 14.77M	£ 12.98M
Dividend Per Share	-	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-	-
Rent Expense Supplemental	-	-	-	-	-	-
Total Expenses	-	£ 4.56M	£ 4.04M	£ 3.09M	£ 1.39M	£ 1.09M
Net Income From Continuing And Discontinued Operation	-	£ -2.00M	£ -2.07M	£ -1.45M	£ -816.00K	£ -609.00K
Normalized Income	-	£ -2.64M	£ -2.65M	£ -1.46M	£ -782.34K	£ -603.00K
Interest Expense	-	-	-	-	-	-
EBIT	-	£ -2.31M	£ -2.35M	£ -1.56M	£ -904.00K	£ -632.00K
EBITDA	-	£ -1.95M	£ -2.04M	£ -1.29M	£ -710.00K	£ -414.00K

Currency in GBP

RUA Life Sciences Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing